Asset comparator
Compare stocks, ETFs, indices, commodities, cryptocurrencies and bonds over the same period. Indicators that are not meaningful for a given asset type are flagged.
- EssilorLuxottica
- Novartis
Rentabilidad comparada (base 100)
Cada activo vale 100 el 13 de octubre de 2025; un valor de 120 significa +20 % desde esa fecha (última fecha común: 9 de octubre de 2026).
Each performance is calculated in the asset's trading currency, without currency conversion.
Indicadores
«N/A» indica un indicador que no tiene sentido para este tipo de activo: no debe compararse.
| Indicador | EssilorLuxotticaStock | NovartisStock |
|---|---|---|
| Rentabilidad y riesgo | ||
| Performance over the periodChange in price between the first and last common dates. | −46.7% | +14.0% |
| Annualized performanceAverage annual return that would produce the same total performance. | −47.1% | +14.1% |
| Annualized volatilityTypical range of price movements: the higher it is, the more the price fluctuates. | 32.0% | 23.2% |
| Maximum DrawdownLargest decline from peak to subsequent trough over the period. | −56.7% | −15.0% |
| Sharpe RatioReturn achieved above the risk-free rate (5.24%), per unit of volatility. The higher it is, the better risk was rewarded over the period. | -1.56 | 0.52 |
| 1-day 95% Value at RiskOne-day loss that was exceeded in only 5% of cases (historical VaR). | −3.5% | −2.2% |
| Fundamentales | ||
| Market capitalizationTotal market value of all shares (or circulating tokens for a crypto). | 67.08B € | 226.38B CHF |
| P/E (trailing 12 months)Share price divided by earnings per share: number of years of earnings paid. | 27.4 | 22.7 |
| Price-to-SalesMarket capitalization divided by annual revenue. | 2.3 | 4.0 |
| Net marginShare of revenue retained as profit. | 8.5% | 22.5% |
| Return on equityReturn on equity (ROE). | 6.7% | 30.3% |
| Revenue growthOver one year, latest published quarter compared with the same quarter of the previous year. | +5.7% | +0.8% |
| Dividend yieldAnnual dividend relative to the share price. | 2.80% | 3.14% |
| Debt / equityFinancial debt relative to shareholders' equity. | 38% | 117% |
Correlaciones en el periodo
De −1 a 1: cerca de 1, los dos activos suben y bajan juntos; cerca de 0, evolucionan de forma independiente.
- EssilorLuxottica / Novartis0,08
Análisis comparativo
Análisis generado por IALa IA compara los activos seleccionados solo a partir de las cifras anteriores, señalando lo que no es comparable. El texto solo se genera a petición suya.
Información facilitada con fines pedagógicos. No constituye asesoramiento en inversiones ni una recomendación personalizada. Las rentabilidades pasadas no garantizan las rentabilidades futuras.